MoonLake Immunotherapeutics shows severe cash burn acceleration with operating losses nearly doubling to -$227.3M while total liabilities surged 388.8% to $120M, despite increased cash reserves.
The dramatic increase in operating cash outflow from -$116.6M to -$196.0M, combined with net losses expanding 91% to -$227.3M, signals unsustainable burn rates that could threaten the company's ability to fund operations through drug development milestones. While cash increased to $334.5M providing some runway, the 388.8% spike in total liabilities to $120M raises questions about new debt obligations or accrued expenses that weren't fully disclosed.
The financial profile shows a company in aggressive development phase with concerning cash management dynamics. While cash reserves increased 85% to $334.5M (likely from financing activities), operating losses nearly doubled and total liabilities quadrupled, creating a precarious balance between funding runway and burn acceleration. The 80% increase in R&D expenses to $202.9M explains much of the deterioration but raises sustainability concerns, while the massive liability increase suggests either new debt facilities or significant accrued obligations that warrant close monitoring.
Liabilities grew 388.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 102.4% — significant near-term obligations; verify ability to meet short-term debt.
Capex reduced 93.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Net income declined 91.1% — review whether driven by operations, interest costs, or non-recurring items.
Cash position surged 85.4% — strong cash generation or capital raise providing significant financial cushion.
R&D investment increased 79.9% — signals commitment to future product development, though near-term margin impact.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow fell 68.1% — earnings quality concerns; investigate working capital changes and non-cash items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 11.2% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →